Adherence and persistence with glaucoma therapy.

Greater Baltimore Medical Center, Baltimore, Maryland 21204, USA.
Survey of Ophthalmology (Impact Factor: 3.51). 11/2008; 53 Suppl1:S57-68. DOI: 10.1016/j.survophthal.2008.08.002
Source: PubMed

ABSTRACT Adherence and persistence with chronic therapies is crucial to prevent disease progression, such as in glaucoma. Patients report high rates of adherence, which are not supported by pharmacy claims analysis. This article reviews the literature regarding methods to assess adherence and persistence and the patient behaviors that pose challenges to proper treatment. Rates for persistence are generally below 50% at 1 year. Differentiating efficacy of eyedrops from lack of adherence presently confounds ophthalmic treatment. Additionally, as intraocular pressure (IOP) can appear controlled by short-term adherence, the physician can be fooled into believing the patient's glaucoma is well-controlled. Likewise, when progressive worsening is noted despite good IOP control, it can be problematic whether the patient's target pressure needs to be lowered or adherence needs to be improved. White-coat adherence is common, in which patient adherence rises sharply 1 week before the appointment with the physician, then declines rapidly following the appointment. White-coat adherence may make it difficult to assess IOP control over the longer term; cycling behavior with medication use is well-documented. Adherence and persistence rates differ by class of drug, with higher rates associated with prostaglandin use. We review findings from The Glaucoma Adherence and Persistency Study that identified behaviors associated with poor adherence. Greater physician awareness of adherence and persistence issues is necessary in order to help the patient become more adherent.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We combine laboratory-based timolol release studies and in vivo pharmacodynamics studies in beagle dogs to evaluate the efficacy of glaucoma therapy through extended wear contact lenses. Commercial contact lenses cannot provide extended delivery of ophthalmic drugs and so the studies here focused on increasing the release duration of timolol from ACUVUE TruEye contact lenses by incorporating vitamin E diffusion barriers. The efficacy of timolol delivered via extended wear contact lenses was then compared to eye drops in beagle dogs that suffer from spontaneous glaucoma. The lenses were either replaced every 24h or continuously worn for 4 days, and the pharmacodynamics effect of changes in the intraocular pressure (IOP) of timolol from the ACUVUE TruEye contact lenses can be significantly increased by incorporation of vitamin E. The in vivo studies showed that IOP reduction from baseline by pure contact lens on daily basis was comparable with that by eye drops but with only 20% of drug dose, which suggested higher drug bioavailability for contact lenses. In addition, by inclusion of vitamin E into the lenses, the IOP was reduced significantly during the 4-day treatment with continuous wear of lens.
    Journal of Controlled Release 06/2012; 162(1):152-8. DOI:10.1016/j.jconrel.2012.06.017 · 7.26 Impact Factor
  • Source
    Glaucoma - Current Clinical and Research Aspects, 11/2011; , ISBN: 978-953-307-263-0
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glaucoma is an optic neuropathy that is usually associated with an elevated intraocular pressure. Primary open-angle glaucoma (POAG) is the most common type of glaucoma and is progressive and bilateral but typically asymmetric in patients. Studies have shown that reducing intraocular pressure reduces the risk of vision loss. In the United States, medical intervention by means of prescription eye drops is the initial line of treatment. Nurses play an important role in educating individuals, particularly older adults, about the importance of routine eye care to earlier diagnose, treat, and adequately manage eye diseases such as POAG.
    Journal of Gerontological Nursing 03/2011; 37(3):10-5. DOI:10.3928/00989134-20110210-01 · 0.62 Impact Factor


Available from